Moderna Inc. is the second pharmaceutical in a week to announce that an independent monitoring board has found its vaccine highly effective against COVID-19.
Last Monday, Pfizer’s Phase 3 vaccine showed a 90% success rate in fighting the virus.
“This is a pivotal moment in the development of our COVID-19 vaccine candidate.
The 95 COVID-19 cases included 15 adults over 65, and 20 people identifying as being from diverse communities, including 12 Hispanic or Latino, four Black, three Asian American and one multiracial.
The challenge is going to be getting people to accept the vaccine.”Both the Pfizer and Moderna vaccines use genetics to provoke an immune response in the coronavirus genes.